An FDA advisory panel has recommended easing restrictions on certain peptides, despite warnings from government scientists about insufficient evidence on their safety and effectiveness. Peptides have gained popularity among wellness influencers and celebrities, who claim they offer antiaging and anti-inflammatory benefits and support longevity. The panel’s suggestion could allow specific pharmacies to produce substances like BPC-157, KPV, and TB-500 and dispense them through prescriptions.
The vote by the FDA’s Pharmacy Compounding Advisory Committee was 8-6, with one abstention, to add BPC-157, KPV, and TB-500 to the agency’s 503A bulk drug substances list. This decision does not mean these peptides are FDA-approved drugs; instead, it is a nonbinding recommendation. Adoption of this recommendation could enable state-licensed compounding pharmacies and physicians to manufacture these substances under certain conditions. Although the FDA often follows the panel’s advice, following it is not mandatory.
Health Secretary and Expert Opinions
Health Secretary Robert F. Kennedy Jr. has expressed support for peptides, pledging to remove FDA restrictions implemented under the Biden administration. He also introduced new members to the agency’s advisory panel, some with interests in peptide-related businesses, as reported by MedPage Today. Newsweek reached out to HHS for comment.
Not all experts are in favor. Dr. Pieter Cohen, an associate professor of medicine at Harvard University, expressed skepticism, telling Newsweek that there’s insufficient evidence confirming the safety of these peptides for human use. He stated that there isn’t enough support for claims of muscle healing, longevity, or antiaging benefits. “The safety of these compounds is unknown in humans,” Cohen stated. “If they were to increase the risk of cancer or heart disease, we wouldn’t know.”
What Are Peptides?
Peptides are short chains of amino acids, the building blocks of proteins. Naturally occurring in the body, peptides regulate processes like inflammation, appetite, pigmentation, tissue repair, and hormone signaling. BPC-157, derived from amino acids in the stomach, shows antioxidant and anti-inflammatory effects in animal preclinical models, but comprehensive human studies are lacking.
KPV, a three-amino-acid peptide from a hormone in the pituitary gland, has been studied for reducing inflammation in gut, skin, and wounds in animal models. However, these studies do not directly translate to human effects. TB-500 is linked to thymosin beta-4, a natural peptide found in human cells, and is associated with cardiac repair, stroke recovery, and wound healing in animal studies. Yet, substantial human data on full-length thymosin beta-4 does not guarantee that TB-500 offers similar benefits.
The Use and Popularity of Peptides
Peptides have gained traction in wellness and “biohacking” communities, marketed for muscle recovery, injury healing, antiaging, sleep, energy, and longevity. These uses are mainly based on cell or animal models, suggesting potential in reducing inflammation and oxidative stress and encouraging wound healing and tissue regeneration. Nonetheless, preclinical findings emphasize that safety and efficacy in humans remain unconfirmed.
Despite this, demand for peptides continues to grow. Market Research Future projected the peptides market to reach $91.79 billion by 2035, up from an estimated $43.12 billion in 2024. North America leads the market, while the Asia-Pacific region experiences the fastest growth.
Rising interest in peptides appears in U.S. Google searches. Peptidesexplorer.com reported a 1,019 percent increase in searches for “how to get peptides” between March 2025 and February 2026. In February 2026, “are peptides safe” topped searches with 27,100, indicating rising interest and safety concerns.
Safety Concerns Surrounding Peptides
FDA scientists have expressed concerns about the limited evidence supporting the safety and efficacy of BPC-157, KPV, and TB-500 for medical use. They also noted potential immunogenicity risk in injectable formulations, which could lead to immune responses in the body.
The advisory panel is also set to vote on three more peptides: emideltide, semax, and epitalon. Emideltide has been researched since 1981, appearing the most studied among the group. However, inconclusive results on its benefits and insufficient nonclinical toxicity studies have highlighted safety issues.
Review Process Implications
Dr. Cohen critiqued the process, saying it “inverts” the standard experimental drug review method. Typically, a panel of experts debates safety and efficacy, prioritizing the benefits over risks. “Experimental drugs lacking evidence of efficacy or safety wouldn’t be presented to an FDA panel. If they were, the panel would vote against approval,” Cohen explained. He argued that peptide decisions compromise the principle of FDA drug approval following detailed clinical trials, opposing the move to enable peptide prescriptions without substantial evidence.